(2015). 5alpha-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA Oncol. http://doi.org/10.1001/jamaoncol.2015.0387
. L. Azoulay
First name
L.
Last name
Azoulay
(2016). Pioglitazone use and risk of bladder cancer: population based cohort study. Bmj. http://doi.org/10.1136/bmj.i1541
. (2016). A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. N Engl J Med. http://doi.org/10.1056/NEJMoa1506115
. (2016). Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. Eur Urol. http://doi.org/10.1016/j.eururo.2016.04.035
. (2016). Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. Bmj. http://doi.org/10.1136/bmj.i5340
. (2016). Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer. Am J Epidemiol. http://doi.org/10.1093/aje/kwv307
. (2016). Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism. Eur Urol. http://doi.org/10.1016/j.eururo.2015.06.022
. (2016). Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. JAMA Intern Med. http://doi.org/10.1001/jamainternmed.2016.1531
. (2017). The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer. Br J Cancer. http://doi.org/10.1038/bjc.2016.375
. (2017). Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care. http://doi.org/10.2337/dc17-0595
.